Major Funds Exit Mednax Holdings Despite Stock Surge

While Mednax shares have demonstrated remarkable strength in recent months, significant institutional players are quietly reducing their exposure. Recent regulatory filings reveal substantial position trimming by Boston Partners and Geode Capital Management, creating a concerning backdrop to the stock’s impressive rally.

Insider Transactions Compound Concerns

Adding to the institutional exodus, corporate insiders have been active sellers in November 2025. Recent disclosures show two directors capitalizing on current price levels:

• November 17: Director Michael Rucker disposed of 10,478 shares at $23.00 each, generating total proceeds of $240,994
• November 6: Director Laura Linynsky sold 10,000 shares at $21.65 per share, realizing $216,500

The convergence of selling activity from both company directors and major financial institutions typically captures significant attention from market researchers looking for directional signals.

Institutional Exodus Gains Momentum

The latest 13F filings paint a clear picture of institutional retreat. Boston Partners executed the most dramatic reduction, liquidating 562,271 shares during the second quarter of 2025—a 28.4% decrease in their stake. This leaves the firm holding approximately 1.4 million shares valued around $20 million.

Simultaneously, Geode Capital Management trimmed its investment by 15,298 shares. These coordinated moves suggest that sophisticated money managers are either securing profits or reallocating capital despite the share price stability.

Should investors sell immediately? Or is it worth buying Mednax?

Financial Performance Presents Mixed Picture

Behind these ownership changes lies a quarterly report for Q3 2025 that delivered contrasting messages. Revenue reached $492.88 million, representing a 3.6% year-over-year decline. However, earnings provided a positive surprise with EPS of $0.67 substantially outperforming the $0.46 consensus estimate.

Despite the revenue contraction, Mednax maintains a substantial market presence with capitalization of approximately $2.06 billion. The stock trades at a P/E ratio between 12.48 and 18.58 depending on calculation methodology, positioning it within reasonable valuation parameters for the healthcare sector.

Key Metrics at a Glance

• Boston Partners sale: -562,271 shares (-28.4%)
• Q3 revenue: $492.88 million (-3.6%)
• Q3 EPS: $0.67 (estimate: $0.46)
• 6-month performance: +71.67%
• Market capitalization: ~$2.06 billion

Divergence Between Price Action and Fundamentals

The disconnect between operational results and market performance appears striking: against a backdrop of declining revenues, the share price has advanced more than 71% over six months, demonstrating exceptional resilience. However, the emerging institutional selling pressure introduces conflicting signals to this upward momentum.

Market experts currently maintain a “Moderate Buy” recommendation with an average price target of $21.00. Given the current trading level around $23.97, this suggests potential downside risk. The critical question for investors remains whether the impressive rally can sustain itself amid these contrasting indicators.